𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Determinants of bone mass, density and growth in growing dogs with normal and osteopenic bones

✍ Scribed by K. Kumar; I. V. Mogha; H. P. Aithal; Amarpal; P. Kinjavdekar; G. R. Singh; A. M. Pawde; H. C. Setia

Publisher
Springer Netherlands
Year
2008
Tongue
English
Weight
142 KB
Volume
33
Category
Article
ISSN
0165-7380

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Increased bone mass, altered trabecular
Increased bone mass, altered trabecular architecture and modified growth plate organization in the growing skeleton of SOCS2 deficient mice
✍ V.E. MacRae; S. Horvat; S.C. Pells; H. Dale; R.S. Collinson; A.A. Pitsillides; S πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 267 KB

## Abstract Suppressor of cytokine signalling‐2 (SOCS2) negatively regulates the signal transduction of several cytokines. __Socs2__^βˆ’/βˆ’^ mice show increased longitudinal skeletal growth associated with deregulated GH/IGF‐1 signalling. The present study examined the role of SOCS2 in endochondral os

Levels of serotonin, sclerostin, bone tu
Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5
✍ Morten Frost; Tom Andersen; Fatma Gossiel; Stinus Hansen; Jens Bollerslev; Wim v πŸ“‚ Article πŸ“… 2011 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 216 KB πŸ‘ 1 views

## Abstract Patients with an activation mutation of the __Lrp5__ gene exhibit high bone mass (HBM). Limited information is available regarding compartment‐specific changes in bone. The relationship between the phenotype and serum serotonin is not well documented. To evaluate bone, serotonin, and bo

Density and structural changes in the bo
Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge
✍ J.A. Spadaro; T.A. Damron; J.A. Horton; B.S. Margulies; G.M. Murray; D.A. Clemen πŸ“‚ Article πŸ“… 2006 πŸ› Elsevier Science 🌐 English βš– 257 KB

## Abstract Alendronate (ALN) and other bisphosphonates have been used successfully in pediatric patients with osteopenia secondary to connective tissue diseases. Loss of growth in height has not been reported, but concerns remain regarding the effect of these potent antiresorptive agents when used